BioTech IP Review

Patent Number: U.S. 7,601,740 B2
Patent Subject: Composition of pimavanserin (the active molecule in Acadia’s Parkinson’s disease psychosis drug)
Status in 2025: Validated by U.S. Court of Appeals for the Federal Circuit in June 2025 (affirming earlier lower court ruling)
Patent Protection Extended: Protection for Nuplazid into 2030 based on this patent and reinforced by litigation wins in 2025.

Note: While this patent was originally filed and granted years earlier, its validation and strongest enforcement outcomes make it arguably the most important and lucrative IP event for Acadia, because it protects its core revenue drug from generic competition — a major commercial advantage.

---

What This Patent Covers

• Core Molecule Protection: The ’740 patent covers the composition of matter for pimavanserin, the active molecule in NUPLAZID®, which is the first and only FDA‑approved therapy specifically for hallucinations and delusions associated with Parkinson’s disease psychosis.
• Composition‑of‑Matter Claims: Composition patents typically protect the actual chemical entity itself — meaning no competitor can sell the same molecule legally without a license while this patent remains valid.
• Lawsuit Reinforcement: In 2025 Acadia fought ANDA (generic) challenges and the U.S. Court of Appeals for the Federal Circuit affirmed the patent’s validity after lower court rulings, cementing exclusivity for the molecule into at least 2030.

---

Why This Patent Is Important

1) Protects Acadia’s Main Revenue Source
Nuplazid remains a lead product for Acadia, with substantial ongoing sales as a treatment for Parkinson’s disease psychosis. Securing its composition patent into 2030 safeguards these revenues against cheaper generics.

2) Strengthened by Legal Wins in 2025
In 2025, Acadia successfully defended this patent through appellate litigation, with the U.S. Court of Appeals upholding the patent’s validity against challenges — a significant confirmation of its enforceability.

3) Foundation for Additional Exclusivity
Although formulation patents (e.g., U.S. Patent No. 11,452,721 covering the capsule form) protect Nuplazid into 2038, the underlying composition patent remains the foundational intellectual property on the active molecule itself — giving Acadia a broad IP fortress around its core asset.

4) Commercial Impact
Without this patent defense, generic entrants could enter the market sooner, drastically reducing Acadia’s share and pricing power. Successfully defending it in 2025 was a major commercial and strategic win.